1 week Ago By Defense World Staff
Shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) saw strong trading volume on Friday . 2,386,364 shares changed hands during mid-day trading, an increase of 191% from the previous session’s volume of 820,287 shares.
The stock last traded at $97.76 and had previously closed at $99.95.
Analyst Ratings ChangesA number of research firms recently commented on CRL. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $190.00 to $170.
00 in a report on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price target for the stock from $155.00 to $175.
00 in a research note on Tuesday, March 4th. Barclays lowered their target price on shares of Charles River Laboratories International from $160.00 to $145.
00 and set an “equal weight” rating on the stock in a research note on Thursday. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.
00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Finally, Mizuho dropped their price target on shares of Charles River Laboratories International from $175.00 to $155.
00 and set a “neutral” rating for the company in a research report on Wednesday. One analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. According to data from MarketBeat.
com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus target price of $182.00.Check Out Our Latest Analysis on CRLCharles River Laboratories International Price PerformanceThe stock’s 50-day moving average price is $156.
71 and its 200-day moving average price is $177.01. The company has a quick ratio of 1.
14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.
The company has a market capitalization of $4.89 billion, a price-to-earnings ratio of 663.71, a price-to-earnings-growth ratio of 4.
54 and a beta of 1.45. Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th.
The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.
16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.
69%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million.
During the same quarter in the previous year, the business earned $2.46 EPS. The firm’s revenue was down 1.
1% on a year-over-year basis. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.
36 earnings per share for the current year. Insider Buying and SellingIn related news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th.
The shares were sold at an average price of $162.50, for a total value of $715,000.00.
Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.
02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th.
The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82.
Following the completion of the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.
83 % increase in their position. The disclosure for this purchase can be found here. 1.
30% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On Charles River Laboratories InternationalA number of institutional investors have recently modified their holdings of CRL. Rothschild Investment LLC increased its stake in shares of Charles River Laboratories International by 480.
0% in the first quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock valued at $26,000 after buying an additional 144 shares during the period. Versant Capital Management Inc lifted its holdings in Charles River Laboratories International by 1,071.
4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc.
boosted its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc.
now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. Optiver Holding B.V.
acquired a new stake in Charles River Laboratories International during the 4th quarter worth about $37,000. Finally, GeoWealth Management LLC raised its position in shares of Charles River Laboratories International by 311.5% in the 4th quarter.
GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after acquiring an additional 190 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.
Charles River Laboratories International Company Profile (Get Free Report)Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).Further ReadingFive stocks we like better than Charles River Laboratories InternationalWhen to Sell a Stock for Profit or LossRobinhood Strategies Could Be a Game-Changer for Young InvestorsTrading Stocks: RSI and Why it’s UsefulAre These 3 Retail Stocks Oversold or Really in Trouble?Why Special Dividends Can be a Delightful Surprise for Income InvestorsIONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead.
